Upjohn's Rogaine self-selection studies praised by NDAC member.
This article was originally published in The Tan Sheet
Executive Summary
PHARMACIA & UPJOHN ROGAINE SELF-SELECTION STUDIES "FAIRLY GOOD," FDA Nonprescription Drugs Advisory Committee member Ralph D'Agostino, PhD, Boston University, said at a Nov. 17 joint meeting of NDAC and the Dermatologic and Ophthalmic Drugs Advisory Committee. Commenting on whether the company was able to show that consumers can accurately determine if their hair loss could be treated by OTC Rogaine given the information provided on the product label, D'Agostino described the firm's studies as "fairly good" and the results "pretty respectable."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: